FI72139C - Foerfarande foer framstaellning av anti-t-lymfosyt-globulin. - Google Patents

Foerfarande foer framstaellning av anti-t-lymfosyt-globulin. Download PDF

Info

Publication number: FI72139C
Authority: FI; Finland
Prior art keywords: globulin; lymfosyt; foerfarande foer; foer framstaellning; cells
Prior art date: 1981-02-12

Application number

FI820233A

Other languages

English (en)

Swedish (sv)

Other versions

FI72139B (fi

FI820233L (fi

Inventor

Heidi Thimel-Baumer

Original Assignee

Fresenius Chem Pharm Ind

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-02-12

Filing date

1982-01-26

Publication date

1987-04-13

1982-01-26 Application filed by Fresenius Chem Pharm Ind filed Critical Fresenius Chem Pharm Ind

1982-08-13 Publication of FI820233L publication Critical patent/FI820233L/fi

1986-12-31 Publication of FI72139B publication Critical patent/FI72139B/fi

1987-04-13 Application granted granted Critical

1987-04-13 Publication of FI72139C publication Critical patent/FI72139C/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/851—Placenta; amniotic fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

Description

1 72139

Anti-T-lymfosyytti-globuliinin valmistus - Förfarande för framställning av anti-T-lymfosyt-globulin

Keksinnön kohteena on anti-T-lymfosyytti-globuliinin valmistus immunisoitujen eläinten seerumista.

Suuritehoisia immuunisuppressiiveja käytetään elinsiirroissa siirrosteeseen kohdistuvan hylkimisen pienentämiseen ja luuydinsiirroissa luovuttajan ja isännän välisten sairauksien hoitoon. Niiden valmistus on tapahtunut tähän mennessä siten, että lymfasoluja ruiskutetaan eläimen, esimerkiksi hevosen tai kaniinin kehoon ja anti-lymfosyytti-globuliini otetaan talteen immunisoidun eläimen seerumista. Tämän valmistusmenetelmän haittana on, että menetelmässä käytetään lymfasoluja, joiden hankkiminen aiheuttaa eettisiä ongelmia ja joita on käytettävissä vain rajoitettu määrä.

Keksinnön tavoitteena on käyttää immunosuppressiivin valmistukseen in vitro kasvatettuja soluja.

Hakija on yllättäen havainnut, että käytettäessä immunisointiin JM-solulinjän soluja on mahdollista valmistaa immuno-suppressiivi, jolla on erinomainen vaikutus. JM-solulinjän valmistus ja ominaisuudet on kuvattu U. Schneider'in, H.U. Schwenk'in ja G. Bornkamm'in julkaisussa, Int. J. Cancer 19, 621-626 (1977). JM-solulinja on tallennettu numerolla I 147 Pasteuer-instituutin kokoelmaan, Institut Pasteuer Collection Nationale de Culture des Microorganismes (C.N.C.M.). Soluja voidaan lisätä mielivaltaisesti in vitro niiden menettämättä ominaisuuksiaan.

Anti-T-lymfosyyttiglobuliini otetaan edullisesti talteen immunisoitujen kaniinien seerumista.

2 72139

Seuraavassa on kuvattu suoritusesimerkki anti-tymosyyttiglobu- liinin valmistamisesta käyttämällä T-lymfoblasti-solulinjaa-JM.

Esimerkki muodostuu seuraavista vaiheista: 1. Sentrifugoidaan T-lymfoblasti-solut.

2. Säädetään solususpensio fysiologisella solualustalla (CL 15), solukonsentraatioon 30 x 10^ solua/ml.

3. Immunisoidaan kaniinit applikoimalla laskimonsisäisesti 3 ml solususpensiota korvalaskimoon.

4. Valutetaan veri eläimistä 4-viikkoisen immunisointiajän jälkeen.

5. Seerumi otetaan talteen sentrifugoimalla veri.

6. Kaniinien veri yhdistetään vasta-ainetiitterin määrittämisen ja steriil isyyden tutkimisen jälkeen.

7. Absorboidaan seerumi erilaisilla ihmissoluilla.

8. Puhdistetaan antiseerumi globuliinifraktiointia varten saostamalla ammoniumsulfaatilla ja sen jälkeen käsittelemällä pylväskromatograafisesti.

9. Immunoglobuliinijae säädetään määrättyyn valkaisuaine-pitoisuuteen (20 mg/ml).

10. Tämän jälkeen ultrasentrifugoidaan anti-tymosyytti-globuliini ja suodatetaan steriiliksi.

11. Immunoglobuliini täytetään ampulleihin ja suoritetaan loppukontrolli (testataan laatu, steriilisyys ja pyrogeenipitoisuus).

FI820233A 1981-02-12 1982-01-26 Foerfarande foer framstaellning av anti-t-lymfosyt-globulin. FI72139C (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19813105150 DE3105150A1 (de)	1981-02-12	1981-02-12	Herstellung von anti-t-lymphozyten-globulin.
DE3105150		1981-02-12

Publications (3)

Publication Number	Publication Date
FI820233L FI820233L (fi)	1982-08-13
FI72139B FI72139B (fi)	1986-12-31
FI72139C true FI72139C (fi)	1987-04-13

Family

ID=6124731

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI820233A FI72139C (fi)	1981-02-12	1982-01-26	Foerfarande foer framstaellning av anti-t-lymfosyt-globulin.

Country Status (19)

Country	Link
US (1)	US4541953A (fi)
AT (1)	AT377698B (fi)
AU (1)	AU550257B2 (fi)
BE (1)	BE891944A (fi)
CA (1)	CA1184491A (fi)
CH (1)	CH652410A5 (fi)
DE (1)	DE3105150A1 (fi)
DK (1)	DK56882A (fi)
ES (1)	ES8401982A1 (fi)
FI (1)	FI72139C (fi)
FR (1)	FR2499413B1 (fi)
GB (1)	GB2093037B (fi)
HU (1)	HU189998B (fi)
IT (1)	IT1195296B (fi)
LU (1)	LU83932A1 (fi)
NL (1)	NL8200458A (fi)
NO (1)	NO157422C (fi)
SE (1)	SE460826B (fi)
ZA (1)	ZA82905B (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3483996D1 (de) *	1983-09-15	1991-02-28	Univ Leland Stanford Junior	Allotransplantat mit verminderter immunogenitaet und verfahren und reagenz fuer seine herstellung.
US4681760A (en) *	1985-04-17	1987-07-21	The Board Of Trustees Of The Leland Stanford Junior University	Method of conferring immunotolerance to a specific antigen
US5011684A (en) *	1985-09-05	1991-04-30	Beth Israel Hospital Association	Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5785966A (en) *	1994-06-15	1998-07-28	Coles; John G.	Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients
FR2878852B1 (fr) *	2000-09-28	2007-02-23	Imtix Sangstat	Procede de production d'immunoglobulines anti-thymocytes humains

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4363799A (en) *	1979-03-20	1982-12-14	Ortho Pharmaceutical Corporation	Monoclonal antibody to human T cells, and methods for preparing same
US4361549A (en) *	1979-04-26	1982-11-30	Ortho Pharmaceutical Corporation	Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4364935A (en) *	1979-12-04	1982-12-21	Ortho Pharmaceutical Corporation	Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
US4361550A (en) *	1979-12-04	1982-11-30	Ortho Pharmaceutical Corporation	Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
US4364933A (en) *	1979-12-04	1982-12-21	Ortho Pharmaceutical Corporation	Monoclonal antibody to a human thymocyte antigen and methods of preparing same

1981
- 1981-02-12 DE DE19813105150 patent/DE3105150A1/de active Granted
- 1981-11-23 GB GB8135192A patent/GB2093037B/en not_active Expired
- 1981-11-24 IT IT25247/81A patent/IT1195296B/it active
- 1981-12-11 FR FR8123180A patent/FR2499413B1/fr not_active Expired
1982
- 1982-01-05 NO NO820014A patent/NO157422C/no unknown
- 1982-01-14 AT AT0011482A patent/AT377698B/de not_active IP Right Cessation
- 1982-01-26 FI FI820233A patent/FI72139C/fi not_active IP Right Cessation
- 1982-01-29 BE BE0/207174A patent/BE891944A/fr not_active IP Right Cessation
- 1982-02-04 SE SE8200639A patent/SE460826B/sv not_active IP Right Cessation
- 1982-02-05 NL NL8200458A patent/NL8200458A/nl not_active Application Discontinuation
- 1982-02-08 CA CA000395714A patent/CA1184491A/en not_active Expired
- 1982-02-10 LU LU83932A patent/LU83932A1/de unknown
- 1982-02-10 DK DK56882A patent/DK56882A/da not_active Application Discontinuation
- 1982-02-11 ES ES509504A patent/ES8401982A1/es not_active Expired
- 1982-02-11 HU HU82426A patent/HU189998B/hu not_active IP Right Cessation
- 1982-02-11 AU AU80373/82A patent/AU550257B2/en not_active Ceased
- 1982-02-12 CH CH905/82A patent/CH652410A5/de not_active IP Right Cessation
- 1982-02-12 ZA ZA82905A patent/ZA82905B/xx unknown
1984
- 1984-02-21 US US06/582,030 patent/US4541953A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
LU83932A1 (de)	1982-07-07
SE460826B (sv)	1989-11-27
SE8200639L (sv)	1982-08-13
NO157422C (no)	1988-03-16
AU8037382A (en)	1982-08-19
NO820014L (no)	1982-08-13
FI72139B (fi)	1986-12-31
FR2499413B1 (fr)	1985-08-30
FI820233L (fi)	1982-08-13
DE3105150C2 (fi)	1989-02-23
DK56882A (da)	1982-08-13
NO157422B (no)	1987-12-07
GB2093037B (en)	1984-07-18
BE891944A (fr)	1982-05-17
ATA11482A (de)	1984-09-15
ES509504A0 (es)	1984-01-16
CA1184491A (en)	1985-03-26
CH652410A5 (de)	1985-11-15
ZA82905B (en)	1982-12-29
FR2499413A1 (fr)	1982-08-13
NL8200458A (nl)	1982-09-01
IT8125247A0 (it)	1981-11-24
ES8401982A1 (es)	1984-01-16
US4541953A (en)	1985-09-17
AU550257B2 (en)	1986-03-13
GB2093037A (en)	1982-08-25
AT377698B (de)	1985-04-25
IT1195296B (it)	1988-10-12
HU189998B (en)	1986-08-28
DE3105150A1 (de)	1982-08-19

Publication	Publication Date	Title
DE3853740T2 (de)	1995-11-09	Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen.
US4309418A (en)	1982-01-05	Anti-tumor agent from human serum and process
Van Meter et al.	1969	Ontogeny of circulating immunoglobulins in normal, bursectomized and irradiated chickens
Gajl-Peczalska et al.	1969	LOCALIZATION OF IMMUNOLOGICAL COMPLEXES FIXING ß1C (C3) IN GERMINAL CENTERS OF LYMPH NODES
Moorhead et al.	1973	IMMUNOLOGIC REACTIONS TO HAPTENS ON AUTOLOGOUS CARRIERS I. PARTICIPATION OF BOTH THYMUS-DERIVED AND BONE MARROW-DERIVED CELLS IN THE SECONDARY IN VITRO RESPONSE
FI72139C (fi)	1987-04-13	Foerfarande foer framstaellning av anti-t-lymfosyt-globulin.
US5262334A (en)	1993-11-16	Method for immunoselection of cells using avidin and biotin
Benda et al.	1970	Demonstration of an astrocyte-specific cerebroprotein by an immunofluorescence study of human brain tumors
US4009257A (en)	1977-02-22	Preparation of immunosuppressive materials
DE69525060T2 (de)	2002-11-14	Entzündungshemmende faktor, methode seiner isolation und verwendung
Goldstein et al.	2019	mAbs to human lymphocyte surface antigens
Johnson et al.	1977	Antibody-Mediated Suppression of Tumor Growth: I. Suppression by Murine IgG1 Isolated from Alloantiserum
Aber et al.	1966	Liver function after myocardial infarction
Kashiwagi et al.	1970	Antibody localization in horse, rabbit, and goat antilymphocyte sera
Malchow et al.	1972	Solubilization and partial purification of lymphocyte specific antigens in the chicken
CA1188243A (en)	1985-06-04	Chemorecruitins of leukocytes and inflamed tissues and process for their preparation
Nishihara et al.	1981	Masugi nephritis produced by the antiserum to heterologous glomerular basement membrane: I. Results in mice
Broder et al.	1980	Characteristics of multiple myeloma as an immunodeficiency disease
Yamana et al.	1974	Antilymphocyte antibody purified by immunoabsorption and elution
EP0419462A1 (en)	1991-04-03	Improved immunotoxin therapies utilizing purified ricin a-chain species
AT396936B (de)	1993-12-27	Hybridoma zell-linien und verfahren zu ihrer herstellung sowie die verwendung der genannten zell-linien zur herstellung von monoklonalen antikörpern
Dorizzi et al.	1975	Increase in the proportion of cells with the C'3 receptor in BALB/c mice bearing mammary tumors
DE68913793T2 (de)	1994-10-27	Ein von einem Human-Human-Hybridom abgeleiteter monoklonaler Antikörper und dessen Verwendung.
SU811530A1 (ru)	1987-08-23	Способ получени вещества,обладающего противоопухолевой активностью
Garcia-Rinaldi et al.	1976	Specific in vitro binding of radiolabeled antibodies to cell surface antigens: Interaction of antihuman thymocyte globulin with human target cells

Legal Events

Date	Code	Title	Description
1998-01-26	MM	Patent lapsed
2004-08-31	MM	Patent lapsed	Owner name: DR. EDUARD FRESENIUS